Randomized controlled feasibility study on an outpatient telemedicine integrative care approach for acute bronchitis patients

Randomized controlled feasibility study on an outpatient telemedicine integrative care approach for acute bronchitis patients - pilot-AIM-BroTher

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

DRKS

Registry ID

DRKS00033113

Enrollment

Registered

2023-11-27

Start date

2024-10-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J20

Interventions

Group 1: Integrative telemedicinal outpatient care concept: (adapted to the main complaints of the patients). Patients are contacted on day 1, 2 and 4 via telemedicine by a nurse practitioner. They ar

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Acute bronchitis (diagnosis by primary care physician according to guideline). 2. Onset of symptoms (cough and/or fever > 37.9o C and/or other bronchitis symptoms) < 3 days 3. Signed informed consent by the patient 4. Ability to understand study procedures 5. Age from 18 years old. 6. Equipped to attend telemedicine encounters (smartphone / tablet / laptop / ...)

Exclusion criteria

Exclusion criteria: 1. Bronchitis-like symptoms are primarily attributed to another medical condition, e.g., pertussis, lung cancer, gastroesophageal reflux, heart failure, pulmonary embolism, allergic bronchial asthma, pulmonary tuberculosis 2. Antibiotic treatment during the last 2 weeks 3. Suspected pneumonia 4. Severe cardiac, pulmonary, renal, hepatic insufficiency. 5. Severe psychiatric illness or substance abuse that interferes with protocol- appropriate cooperation 6. Immunosuppression 7. Skin disease that precludes the use of wraps and baths 8. Pregnancy or breastfeeding 9. Participation in another clinical trial

Design outcomes

Primary

Measure	Time frame
Bronchitis Severity Score (BSS) day 7	—

Secondary

Measure	Time frame
• Wisconsin Upper Respiratory Symptom Survey – 21 (day 1-14) • Body temperature (day 1-14) • Quality of Life (EQ-5D, day 1, 4, 7, 14) • Hospitalization rate (during 14/28 days) • Doctor's visits (during 14/28 days) • Prescription of antibiotics, analgesics, anti-inflammatory drugs (during 7/14/28 days) • Use of integrative care measures (day 7) • Patient satisfaction (day 14) • Days of absence from work / school / studies (during 28 days) • Only feasibility trial: Comprehensibility of instructions (day 7) • Only feasibility trial: Feasibility of study procedures and detection of necessary adaptions	—

Measure

Time frame

• Wisconsin Upper Respiratory Symptom Survey – 21 (day 1-14) • Body temperature (day 1-14) • Quality of Life (EQ-5D, day 1, 4, 7, 14) • Hospitalization rate (during 14/28 days) • Doctor's visits (during 14/28 days) • Prescription of antibiotics, analgesics, anti-inflammatory drugs (during 7/14/28 days) • Use of integrative care measures (day 7) • Patient satisfaction (day 14) • Days of absence from work / school / studies (during 28 days) • Only feasibility trial: Comprehensibility of instructions (day 7) • Only feasibility trial: Feasibility of study procedures and detection of necessary adaptions

—

Countries

Germany

Contacts

Public ContactPaul G. Werthmann

Universitätsklinik Freiburg

paul.werthmann@uniklinik-freiburg.de+49 (0) 7 61 / 2 70 82

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026